Preclinical Characterization of Anti-SIRPα mAb BYON422

/PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that the Journal for...

Related Keywords

Netherlands , Nijmegen , Gelderland , Dutch , Marco Timmers , Yvonne Massar , Wim Dokter , Prnewswire Byondis , Public Eyes Healthcare Communications , Society For Immunotherapy Of Cancer , Corporate Communications , Byondi Lead , Enter Phasei Study This , Signal Regulatory Protein , Chief Scientific Officer Wim Dokter , Chief Executive Officer Marco Timmers , Good Manufacturing Practice , Public Eyes Healthcare , Byondisbv ,